Optimisation of electrotransfer of plasmid into skeletal muscle by pretreatment with hyaluronidase – increased expression with reduced muscle damage

[1]  邊見 弘明,et al.  A Toll-like receptor recognizes bacterial DNA , 2003 .

[2]  H. Schaff,et al.  Exogenous hyaluronidase induces release of nitric oxide from the coronary endothelium. , 2000, The Journal of thoracic and cardiovascular surgery.

[3]  G. Ciliberto,et al.  Gene electrotransfer results in a high-level transduction of rat skeletal muscle and corrects anemia of renal failure. , 2000, Human gene therapy.

[4]  R. Hällgren,et al.  Hyaluronidase Can Be Used to Reduce Interstitial Edema in the Presence of Heparin , 2000, Journal of cardiovascular pharmacology and therapeutics.

[5]  L. Mir,et al.  Efficient DNA electrotransfer into tumors. , 2000, Bioelectrochemistry.

[6]  M J Jaroszeski,et al.  Theory and in vivo application of electroporative gene delivery. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[7]  P. Lipsky,et al.  The Role of Cell Surface Receptors in the Activation of Human B Cells by Phosphorothioate Oligonucleotides1 , 2000, The Journal of Immunology.

[8]  N. Ferry,et al.  Hyaluronidase enhances recombinant adeno-associated virus (rAAV)-mediated gene transfer in the rat skeletal muscle , 2000, Gene Therapy.

[9]  H. Madry,et al.  Efficient lipid-mediated gene transfer to articular chondrocytes , 2000, Gene Therapy.

[10]  R. Schwartz,et al.  Myogenic expression of an injectable protease-resistant growth hormone–releasing hormone augments long-term growth in pigs , 1999, Nature Biotechnology.

[11]  D. Scherman,et al.  Erythropoietin secretion and physiological effect in mouse after intramuscular plasmid DNA electrotransfer , 1999, Journal of Gene Medicine.

[12]  R. Cortese,et al.  Efficient and regulated erythropoietin production by naked DNA injection and muscle electroporation. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[13]  M. Bureau,et al.  High-efficiency gene transfer into skeletal muscle mediated by electric pulses. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[14]  I. Mathiesen.  Electropermeabilization of skeletal muscle enhances gene transfer in vivo , 1999, Gene Therapy.

[15]  M. Fiszman,et al.  Gene delivery to the myocardium by intrapericardial injection , 1999, Gene Therapy.

[16]  C. Halbert,et al.  Successful Readministration of Adeno-Associated Virus Vectors to the Mouse Lung Requires Transient Immunosuppression during the Initial Exposure , 1998, Journal of Virology.

[17]  H. Mischak,et al.  CpG‐DNA‐specific activation of antigen‐presenting cells requires stress kinase activity and is preceded by non‐specific endocytosis and endosomal maturation , 1998, The EMBO journal.

[18]  A. Krieg,et al.  Rapid induction of mitogen-activated protein kinases by immune stimulatory CpG DNA. , 1998, Journal of immunology.

[19]  T. Jakob,et al.  Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. , 1998, Journal of immunology.

[20]  K. Wells,et al.  Inflammatory responses following direct injection of plasmid DNA into skeletal muscle , 1998, Gene Therapy.

[21]  D. Wells,et al.  Evaluation of plasmid DNA for in vivo gene therapy: factors affecting the number of transfected fibers. , 1998, Journal of pharmaceutical sciences.

[22]  L. Turka,et al.  Blunting of immune responses to adenoviral vectors in mouse liver and lung with CTLA4Ig , 1998, Gene Therapy.

[23]  R. K. Evans,et al.  Analysis of plasmid DNA from a pharmaceutical perspective. , 1998, Journal of pharmaceutical sciences.

[24]  J. Wolff,et al.  The efficient expression of intravascularly delivered DNA in rat muscle , 1998, Gene Therapy.

[25]  L. Manzel,et al.  Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinacrine, chloroquine, and structurally related compounds. , 1998, Journal of immunology.

[26]  H. Aihara,et al.  Gene transfer into muscle by electroporation in vivo. , 1998, Nature biotechnology.

[27]  H. Herweijer,et al.  High expression of naked plasmid DNA in muscles of young rodents. , 1997, Human molecular genetics.

[28]  James M. Wilson,et al.  Recombinant adeno-associated virus for muscle directed gene therapy , 1997, Nature Medicine.

[29]  R. Samulski,et al.  Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector , 1996, Journal of virology.

[30]  K. Campbell,et al.  In vivo muscle gene transfer of full-length dystrophin with an adenoviral vector that lacks all viral genes. , 1996, Gene therapy.

[31]  A. Fassati,et al.  Transplantation of retroviral producer cells for in vivo gene transfer into mouse skeletal muscle. , 1996, Human gene therapy.

[32]  F. Szoka,et al.  Characterization of plasmid DNA transfer into mouse skeletal muscle: evaluation of uptake mechanism, expression and secretion of gene products into blood. , 1996, Gene therapy.

[33]  A. Fassati,et al.  Efficiency of in vivo gene transfer using murine retroviral vectors is strain-dependent in mice. , 1995, Human gene therapy.

[34]  S. Parker,et al.  Cancer gene therapy using plasmid DNA: pharmacokinetic study of DNA following injection in mice. , 1995, Human gene therapy.

[35]  G. Bishop,et al.  CpG motifs in bacterial DNA trigger direct B-cell activation , 1995, Nature.

[36]  J. Wolff,et al.  Pharmacological enhancement of in vivo foreign gene expression in muscle. , 1994, Gene Therapy.

[37]  A. Picard,et al.  Gene transfer in regenerating muscle. , 1994, Human gene therapy.

[38]  B. Demeneix,et al.  Plasmid DNA is superior to viral vectors for direct gene transfer into adult mouse skeletal muscle. , 1993, Human gene therapy.

[39]  D. Wells.  Improved gene transfer by direct plasmid injection associated with regeneration in mouse skeletal muscle , 1993, FEBS letters.

[40]  M. Perricaudet,et al.  Long–term correction of mouse dystrophic degeneration by adenovirus–mediated transfer of a minidystrophin gene , 1993, Nature genetics.

[41]  A. Rundell,et al.  Gene therapy by intramuscular injection of plasmid DNA: studies on firefly luciferase gene expression in mice. , 1993, Human gene therapy.

[42]  B. Demeneix,et al.  Direct gene transfer into skeletal muscle in vivo: factors affecting efficiency of transfer and stability of expression. , 1993, Human gene therapy.

[43]  D. Wells,et al.  Age and sex influence expression of plasmid DNA directly injected into mouse skeletal muscle , 1992, FEBS letters.

[44]  G. Repetto,et al.  Direct gene transfer into nonhuman primate myofibers in vivo. , 1992, Human gene therapy.

[45]  K. Davies,et al.  Human dystrophin expression in mdx mice after intramuscular injection of DNA constructs , 1991, Nature.

[46]  G. Acsadi,et al.  Direct gene transfer into mouse muscle in vivo. , 1990, Science.

[47]  D. Jenkins,et al.  3-Aminopropyltriethoxysilane (APES): a new advance in section adhesion. , 1987, Journal of clinical pathology.

[48]  T. Dubensky,et al.  Direct transfection of viral and plasmid DNA into the liver or spleen of mice. , 1984, Proceedings of the National Academy of Sciences of the United States of America.